Panomix announced the completion of a Series A+ financing round of nearly 100 million yuan. The funds raised in this round will primarily be used to accelerate the development of the single-cell multi-omics technology platform and expand the layout of clinical flagship product lines, advancing research in cutting-edge metabolomics technology and innovative clinical applications.

Established in 2013, Panomix is one of the earliest and largest metabolomics companies in China. As a leader in the fields of life sciences and healthcare, the company focuses on advanced technological research in metabolomics and the development of clinical applications. It has built an integrated platform that spans metabolomics, clinical products, and big data analysis. Its business covers scientific research services, industrial services, new drug services, clinical inspection services, clinical products, and health management. Panomix is committed to becoming a comprehensive provider of metabolomics precision medicine and precision nutrition, serving as a metabolic steward for individuals.

Through continuous research and development accumulation and technological innovation, the company has completed several metabolomics technologies and application research at an internationally advanced level. It offers more than 100 testing and analysis services, as well as over 20 clinical testing products. The company also has multiple innovative product development pipelines, covering diagnostics, early screening, and medication guidance in areas such as cardiovascular diseases, stroke, tumors, and gut microbiota. During the same period, the company has been recognized as a leading technology enterprise and a high-tech enterprise. It has obtained ISO9001 certification, CMA (China Metrology Accreditation) license, and medical laboratory qualifications, becoming a leader in the industry.

Driven by the broad and urgent clinical demand, clinical mass spectrometry has developed rapidly in China in recent years. Metabolomics, situated downstream of gene regulation and protein interaction networks, filters out gene/protein "noise" and provides comprehensive biological endpoint information. By combining the technical advantages of mass spectrometry, such as high sensitivity, high resolution, and high throughput, it offers more precise and individualized diagnostic and treatment bases for clinical applications. In 2022, Panomix completed the construction of a comprehensive clinical mass spectrometry service platform, leading with clinical research and supported by innovative clinical products. It also expanded its presence in the life sciences and healthcare fields, extended product coverage, and continued to promote the development of metabolomics-empowered precision medicine.

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.